Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314327 · ClinicalTrials.gov registry record · Phase 4
Optimizing Response in Psychosis Study
A Phase 4 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00314327: Clinical Trial Phase 4 study, sponsored by Northwell Health.
NCT00314327 is a Phase 4 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00314327, a Phase 4 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during their initial treatment trial.
Interventions
- DRUG long-acting injectable risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-04 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Why NCT00314327 stopped before completion
NCT00314327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which long-acting injectable risperidone is the first listed.
NCT00314327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00314327 about?
NCT00314327 is a clinical study titled "Optimizing Response in Psychosis Study". The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during their initial treatment trial.
What is the current status of trial NCT00314327?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-04. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00314327?
The interventions under investigation include: long-acting injectable risperidone (DRUG).
Who is sponsoring clinical trial NCT00314327?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00314327's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia